Linaclotide Drug Asset Due Diligence Report 2026

This Linaclotide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Linaclotide can convert its Synthetic peptide, Cyclic Peptide profile and GC-C x sGC biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Linaclotide (query alias: linaclotide)
Modality / target	Synthetic peptide, Cyclic Peptide; GC-C x sGC; GC-C agonists, sGC stimulants
Highest global status	Approved
Originator	Ironwood Pharmaceuticals, Inc.
Active developers	AbbVie, Inc., AbbVie AS, Ironwood Pharmaceuticals, Inc.

The MCP disease footprint includes Constipation - functional, Chronic constipation, Chronic idiopathic constipation. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07431957	Phase 4	Not yet recruiting	90	Complete Spontaneous Bowel Movement (CSBM) responder rate
NCT07569419	Early Phase 1	Recruiting	26	Small bowel water content
ChiCTR2500104889	Not Applicable	Notyet recruiting	276	Adenoma detection rate

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment Extension

Phase 3; n=123; evaluation: not stated. Reported fields: Change From Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) Observed by the Primary Caregiver During the Double-blind Study Intervention Period(Least Squares Mean) = 1.738 SBMs/week (Standard Error, 0.2188); Change From Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) Observed by the Primary Caregiver During the Double-blind Study Intervention Period(Least Squares Mean): LS Mean Difference = 0.319(95% CI, -0.2758 to 0.9146), P-Value = 0.2929; Change From Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) Observed by the Primary Caregiver During the Double-blind Study Intervention Period(Least Squares Mean) = 1.418 SBMs/week (Standard Error, 0.2197)

A post hoc analysis of linaclotide in pediatric patients with functional constipation and neurodevelopmental disorders

Phase 3; n=57; evaluation: Positive. Reported fields: SBM(12-week) = 0.59 times/week ; SBM(12-week) = 2.09 times/week

A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Less Than 2 Years of Age With Functional Constipation (FC).

Phase 2; n=19; evaluation: not stated. Reported fields: Observed by the LAR/Parent/Guardian/Caregiver(Mean) = 2.503 SBMs/Week (Standard Deviation, 1.3791); -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Linaclotide addresses Constipation - functional, Chronic constipation, Chronic idiopathic constipation. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-09-18	Ironwood Pharmaceuticals has amended its collaboration agreement with AstraZeneca, granting AstraZeneca exclusive rights to develop, manufacture, and commercialize LINZESS in China, including Hong Kong and Macau	Approved	US$35.0M upfront; US$90.0M milestones; US$125.0M stated total
2015-10-27	Allergan Acquires Rights To Ironwood’s CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries	Approved	Financial terms not disclosed
2015-08-05	Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S.	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combinations of GLP-1 and guanylate cyclase c (GC-c) receptor agonists”. The milestone feed surfaced a patent-application signal described as “Method for purifying linaclotide”. The milestone feed surfaced a patent-application signal described as “Process for the preparation of linaclotide”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO